SCNI NASDAQ
Scinai Immunotherapeutics Ltd.
1W: -14.2%
1M: -43.2%
3M: +394.8%
YTD: +82.3%
1Y: -4.3%
3Y: -84.9%
5Y: -99.4%
$1.33
+0.02 (+1.53%)
Weekly Expected Move ±34.0%
$0
$1
$1
$2
$2
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
2 relationships2
As Filer
counterparties named
0
As Counterparty
mentioned by others
1
Rel. Types
2023-06-08
Earliest Filing
2023-06-08
Latest Filing
licensee: 2
Counterparties (Filed by SCNI)
2 relationshipsCompanies named in SCNI's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Max-Planck-Innovation GmbH | — | licensee | Technology transfer agency of the Max Planck Society in Germany granted an exclusive worldwide license for VHH antibodie | 2023-06-08 | View |
| University Medical Center Gottingen | — | licensee | Partner in the License Agreement granted an exclusive worldwide license for VHH antibodies targeting IL-17. | 2023-06-08 | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR